HK1245125A1 - 包含丙酸氟替卡松和昔萘酸沙美特罗的干粉吸入器 - Google Patents

包含丙酸氟替卡松和昔萘酸沙美特罗的干粉吸入器 Download PDF

Info

Publication number
HK1245125A1
HK1245125A1 HK18104726.3A HK18104726A HK1245125A1 HK 1245125 A1 HK1245125 A1 HK 1245125A1 HK 18104726 A HK18104726 A HK 18104726A HK 1245125 A1 HK1245125 A1 HK 1245125A1
Authority
HK
Hong Kong
Prior art keywords
fluticasone propionate
dry powder
dose
powder inhaler
patient
Prior art date
Application number
HK18104726.3A
Other languages
English (en)
Chinese (zh)
Inventor
Mukul Dalvi
Seah Kee Tee
Original Assignee
Teva Branded Pharmaceutical Products R&D, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55443303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1245125(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Branded Pharmaceutical Products R&D, Inc. filed Critical Teva Branded Pharmaceutical Products R&D, Inc.
Publication of HK1245125A1 publication Critical patent/HK1245125A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0001Details of inhalators; Constructional features thereof
    • A61M15/0005Details of inhalators; Constructional features thereof with means for agitating the medicament
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0001Details of inhalators; Constructional features thereof
    • A61M15/0005Details of inhalators; Constructional features thereof with means for agitating the medicament
    • A61M15/0006Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means
    • A61M15/0008Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means rotating by airflow
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0001Details of inhalators; Constructional features thereof
    • A61M15/0021Mouthpieces therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10Preparation of respiratory gases or vapours
    • A61M16/14Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/06Solids
    • A61M2202/064Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK18104726.3A 2015-01-20 2016-01-20 包含丙酸氟替卡松和昔萘酸沙美特罗的干粉吸入器 HK1245125A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562105479P 2015-01-20 2015-01-20
US62/105,479 2015-01-20
PCT/US2016/014072 WO2016118589A1 (en) 2015-01-20 2016-01-20 Dry powder inhaler comprising fluticasone propionate and salmeterol xinafoat

Publications (1)

Publication Number Publication Date
HK1245125A1 true HK1245125A1 (zh) 2018-08-24

Family

ID=55443303

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18104726.3A HK1245125A1 (zh) 2015-01-20 2016-01-20 包含丙酸氟替卡松和昔萘酸沙美特罗的干粉吸入器

Country Status (19)

Country Link
US (2) US9415008B2 (https=)
EP (1) EP3247331A1 (https=)
JP (1) JP2018503687A (https=)
KR (1) KR20170103975A (https=)
CN (1) CN107530357A (https=)
AR (1) AR104771A1 (https=)
AU (2) AU2016209363B2 (https=)
BR (1) BR112017015353A2 (https=)
CA (1) CA2974125A1 (https=)
CL (1) CL2017001859A1 (https=)
CO (1) CO2017008395A2 (https=)
EA (1) EA201791632A1 (https=)
HK (1) HK1245125A1 (https=)
IL (1) IL253499A0 (https=)
MA (1) MA41378A (https=)
MX (2) MX383344B (https=)
PE (1) PE20171258A1 (https=)
TW (1) TW201628607A (https=)
WO (1) WO2016118589A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX374870B (es) * 2013-10-07 2025-03-06 Teva Branded Pharmaceutical Products R&D Inc Inhalador de polvo seco.
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
US11344685B2 (en) 2016-11-18 2022-05-31 Norton (Waterford) Limited Drug delivery device with electronics
CN110201278B (zh) * 2018-02-28 2021-07-30 张江 用于吸入给药的药盒和吸入给药组合结构
CN110201280B (zh) * 2018-02-28 2021-07-30 张江 用于吸入给药装置的吸嘴和吸入给药装置
CN110201281B (zh) * 2018-02-28 2021-08-06 张江 吸入给药装置和吸入给药组合结构
CN110064110A (zh) * 2019-05-29 2019-07-30 上海理工大学 一种容积旋钮式干粉储存吸入装置
GB2585206B (en) 2019-07-01 2021-08-11 Merxin Ltd Portable inhaler

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
TWI224511B (en) 2000-06-23 2004-12-01 Norton Healthcare Ltd De-agglomerator for breath-actuated dry powder inhaler
TWI224512B (en) * 2000-06-23 2004-12-01 Norton Healthcare Ltd Reservoir pressure system for medicament inhaler
AR030516A1 (es) * 2000-08-31 2003-08-20 Glaxo Group Ltd Uso de una combinacion de salmeterol y fluticasona
ES2474199T3 (es) * 2000-11-30 2014-07-08 Vectura Limited Composiciones farmacéuticas para inhalaci�n
GB0124523D0 (en) * 2001-10-12 2001-12-05 Glaxo Group Ltd Pharmaceutical combination
US20040105821A1 (en) 2002-09-30 2004-06-03 Howard Bernstein Sustained release pharmaceutical formulation for inhalation
US9114081B2 (en) * 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
PL3111927T3 (pl) * 2009-05-29 2020-06-29 Pearl Therapeutics, Inc. Kompozycje do wziewnego podawania środków aktywnych oraz związane z nimi sposoby i systemy
WO2011035128A1 (en) * 2009-09-17 2011-03-24 Mutual Pharmaceutical Company, Inc. Method of treating asthma with antiviral agents
GB0919465D0 (en) 2009-11-06 2009-12-23 Norton Healthcare Ltd Airflow adaptor for a breath-actuated dry powder inhaler
MX339742B (es) * 2010-05-18 2016-06-07 Teva Pharma Ireland Contadores de dosis para inhaladores, inhaladores y flechas de los mismos.
EP2571486A4 (en) 2010-05-20 2013-12-04 Sun Pharma Advanced Res Co Ltd DRY POWDER INHALATION COMPOSITION
KR20130140358A (ko) * 2012-06-14 2013-12-24 한미약품 주식회사 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법
MX2015015150A (es) * 2013-04-29 2016-02-18 Sanofi Sa Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
CA2910976C (en) * 2013-05-03 2021-03-30 Dow Global Technologies Llc Process for equilibrium-limited reactions
MX374870B (es) 2013-10-07 2025-03-06 Teva Branded Pharmaceutical Products R&D Inc Inhalador de polvo seco.
BR112017007587A2 (pt) * 2014-10-16 2018-01-30 Teva Branded Pharmaceutical Products R&D Inc processo para preparar uma formulação farmacêutica em pó seca e inalável
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol

Also Published As

Publication number Publication date
CO2017008395A2 (es) 2018-01-05
TW201628607A (zh) 2016-08-16
CA2974125A1 (en) 2016-07-28
PE20171258A1 (es) 2017-08-28
IL253499A0 (en) 2017-09-28
US20160206559A1 (en) 2016-07-21
AR104771A1 (es) 2017-08-16
WO2016118589A1 (en) 2016-07-28
US20180015035A1 (en) 2018-01-18
MX2021006751A (es) 2021-07-15
US9415008B2 (en) 2016-08-16
AU2021202784A1 (en) 2021-05-27
JP2018503687A (ja) 2018-02-08
AU2016209363B2 (en) 2021-02-04
MX2017009122A (es) 2017-10-12
AU2016209363A1 (en) 2017-08-24
CL2017001859A1 (es) 2018-04-06
CN107530357A (zh) 2018-01-02
EP3247331A1 (en) 2017-11-29
KR20170103975A (ko) 2017-09-13
EA201791632A1 (ru) 2017-12-29
MA41378A (fr) 2017-11-28
MX383344B (es) 2025-03-13
BR112017015353A2 (en) 2018-01-16

Similar Documents

Publication Publication Date Title
HK1222127A1 (zh) 乾粉吸入器
HK1245125A1 (zh) 包含丙酸氟替卡松和昔萘酸沙美特罗的干粉吸入器
HK1198279A1 (en) Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate
MX2013012975A (es) Composiciones farmaceuticas.
WO2009065406A3 (en) Novel cyclic hydrocarbon compounds for the treatment of diseases
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
WO2014064410A8 (en) Pharmaceutical composition
WO2012040228A3 (en) Aerosol composition for administering drugs
MX336225B (es) Composiciones que comprenden sulfato de salbutamol.
MX2019003685A (es) Composicion farmaceutica para uso en el tratamiento terapeutico del cancer y complicaciones del cancer.
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
MX370890B (es) Composición que comprende sulfato de salbutamol.
MX2015015132A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
WO2013104892A8 (en) Application of high dose compounds via inhalation
HK1255584A1 (zh) 使用阿坎酸及d-环丝胺酸的联合疗法
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
HK1222585A1 (zh) 用於提供疼痛减轻和麻醉的二氢埃托啡
WO2016122288A3 (ko) 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
WO2013153349A3 (en) Pharmaceutical composition comprising arformoterol and fluticasone furoate
MX2018005876A (es) Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas.
WO2015130963A3 (en) Compositions and methods for administering insulin or insulin-like protein to the brain
TH173838A (th) เครื่องพ่นละอองยาผงแห้ง
MX2021014343A (es) Una composicion de polvo inhalable de dosis fijas que comprende glicopirronio, formoterol y propionato de fluticasona.
WO2014016613A3 (en) Type b lantibiotic nvb302 for the treatment of c. difficile infection